Dart Neuroscience, (cayman) Ltd.

Ariad Pharmaceuticals, Inc.

Ariad Gene Therapeutics, Inc.

Dart Neuroscience, LLC

Helicon Therapeutics, Inc.

Terence P Keenan

Alan P Kaplan

Wu Yang

Dennis Alan Holt

Andrew J McRiner

Tao Guo

Leonard W Rozamus

Edgardo Laborde

Michael Z Gilman

Timothy P Clackson

Rusiko Bourtchouladze

Roderick E M Scott

Xianbo Zhou

Mi Chen

William Charles Ripka

Mark E Wilson

Michael I Weinhouse

Andrew Lindstrom

Andrew J Mcriner

William C Shakespeare

Tomi K Sawyer

Laurent Gomez

David C Dalgarno

Kiev S Ly

James Breitenbucher

Manfred Weigele

Robert Huerta Lemus

Tami Jo Marrone

Amy Lynn Allan

John D Iuliucci

Roderick Em Scott

Andrew Mcriner

Roderick EM Scott

Andrew Mckriner

The invention provides a chemical entity of Formula (I): (I), wherein R, R, R, and R, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors

The invention provides a compound of formula I: wherein A, A, A, R, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase B (MAO-B) enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals.

Therapeutic isoxazole compounds

The invention includes a compound of formula I: wherein R, Y, A, n, Rand Z have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function and/or treating cognitive disorders or impairment, traumatic and/or ischemic injuries of the central and peripheral nervous system and/or psychiatric disorders in animals, especially humans.

Therapeutic piperazines

The invention provides a compound of formula I: wherein R-R, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of MAO-B enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals.

Therapeutic compounds

The invention includes a compound of formula I:  wherein R, X, Z, n, and m have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function in animals.

Piperazine PDE4 inhibitors and uses thereof

New compounds are disclosed for multimerizing immunophilins and proteins containing immunophilin or immunophilin-related domains. The compounds are of the formulaM-L-Qwhere M is a synthetic ligand for an FKBP protein.

Synthetic multimerizing agents

Pyrazole compounds and uses thereof

The invention includes a compound of formula I: 

Growing community of inventors

Bay Shore, NY, United States of America

Terence P Keenan